Focus on frailty: New senolytic holds potential for sarcopenia treatment

Posted by | Nov 22, 2022 | Senolytic News | 0 |

Buck Institute professor shifts focus to functional studies of senolytic compound with hopes for frailty and sarcopenia.

Recent News in Senolytics

The Senolytics Showdown: Unpacking the Recent Controversy
Apr 19, 2024 | Senolytic News
The Promise of Senolytic Therapies
Oct 2, 2023 | Senolytic News
AI Unlocks New Frontier in Anti-Aging Medicine
Aug 24, 2023 | Senolytic News
Reversing Aging in Stem Cells
Jun 29, 2023 | Uncategorized
Fighting aging with immune checkpoint blockade
Nov 23, 2022 | Senolytic News
Despite Their Scary Name, Some ‘Zombie’ Cells May Not Be All Bad
Nov 23, 2022 | Senolytic News
Focus on frailty: New senolytic holds potential for sarcopenia treatment
Nov 22, 2022 | Senolytic News
Progress in Emerging Alzheimer’s Therapeutics Based on Biology of Aging to be Highlighted in Session Moderated by Alzheimer’s Drug Discovery Foundation (ADDF) at 2022 Clinical Trials on Alzheimer’s Disease Conference
Nov 21, 2022 | Senolytic News
Senolytic treatment shows promise in DME, wet AMD
Nov 20, 2022 | Senolytic News
Global Senolytic Drugs Market Research Report 2022: Voice of Customer, Clinical Trials, Patent Analysis, Outlook, Market Dynamics, Trends & Developments, Competitive Landscape
Nov 19, 2022 | Senolytic News
A Glb1-2A-mCherry reporter monitors systemic aging and predicts lifespan in middle-aged mice
Nov 19, 2022 | Senolytic News
Senolytics to Tackle Age-Related Pathologies
Nov 19, 2022 | Senolytic News

	Enter eToro US
	Enter eToro International